Dr. N.L. Tiwari Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 5.95%
- Profit Growth -39.59%
- Ebitda 484.11%
- Net Worth -1.21%
- Total Assets 7.97%
About Dr. N.L. Tiwari Pharmaceuticals
Dr. N.L. Tiwari Pharmaceuticals Private Limited (DNTPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 May 2005 and has a history of 19 years and eight months. Its registered office is in Jaipur, Rajasthan, India.
The Corporate was formerly known as Dr. Nand Lal Tiwari Pharmaceuticals Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ2005PTC020802
-
Company No.
020802
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 May 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Dr. N.L. Tiwari Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Tiwari
|
Director | 25-May-2005 | Current |
|
Vipin Tiwari
|
Director | 17-Jan-2020 | Current |
Financial Performance of Dr. N.L. Tiwari Pharmaceuticals.
Dr. N.L. Tiwari Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 5.95% increase. The company also saw a substantial fall in profitability, with a 39.59% decrease in profit. The company's net worth dipped by a decrease of 1.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. N.L. Tiwari Pharmaceuticals?
In 2019, Dr. N.L. Tiwari Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Om Medipharmaceuticals Private LimitedPawan Tiwari and Vipin Tiwari are mutual person
-
Omp Pharma Private LimitedVipin Tiwari is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr. N.L. Tiwari Pharmaceuticals?
Unlock and access historical data on people associated with Dr. N.L. Tiwari Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. N.L. Tiwari Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. N.L. Tiwari Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
